Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × pirarubicin × Clear all
NCT07178171 2025-11-24

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Xijing Hospital

Phase 1 Recruiting
30 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡